← Leaderboards
Dominic J Ciavatta
Univ Of North Carolina Chapel Hill
$2,618,471
Attributed
$5,147,607
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $682.7K · FY2015–24$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$5,147,607 · 2
By mechanism
R01$3,372,181 · 1
P01$1,775,426 · 1
Top collaborators
- Ronald J Falk5 shared
- Meghan Free5 shared
- Charles Jennette5 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Charles Jennette$2,659,979
- Meghan Free$843,045
- Erin C Garcia$2,310,570
- Vimal Kumar Derebail$1,143,308
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularVariantVasculitisNovel TherapeuticsTargeted TreatmentT-LymphocyteDisease RemissionGene ExpressionGranulocyteNeutrophilPathogenesisPrtn3 GeneAutoantibodiesAutoantigensCellsAutoimmune DiseasesDna MethylationEpigenetic ProcessAutoimmunityGlomerulonephritisMonocyteLeadGenetic TranscriptionNovel Therapeutic Intervention
Grant awards (10)
Pathobiology of ANCA Glomerulonephritis: Targeting Adaptive and Innate Immune Processes for Precision Therapies$653,602
R01 · FY2024 · DK
Pathobiology of ANCA Glomerulonephritis: Targeting Adaptive and Innate Immune Processes for Precision Therapies$682,709
R01 · FY2023 · DK
Pathobiology of ANCA Glomerulonephritis: Targeting Adaptive and Innate Immune Processes for Precision Therapies$679,218
R01 · FY2022 · DK
Pathobiology of ANCA Glomerulonephritis: Targeting Adaptive and Innate Immune Processes for Precision Therapies$677,829
R01 · FY2021 · DK
Pathobiology of ANCA Glomerulonephritis: Targeting Adaptive and Innate Immune Processes for Precision Therapies$678,823
R01 · FY2020 · DK
Genetic variants in ANCA glomerulonephritis and molecular signatures of disease states.$358,265
P01 · FY2019 · DK · contact PI
Genetic variants in ANCA glomerulonephritis and molecular signatures of disease states.$364,295
P01 · FY2018 · DK · contact PI
Genetic variants in ANCA glomerulonephritis and molecular signatures of disease states.$357,711
P01 · FY2017 · DK · contact PI
Genetic variants in ANCA glomerulonephritis and molecular signatures of disease states.$348,787
P01 · FY2016 · DK · contact PI
Genetic variants in ANCA glomerulonephritis and molecular signatures of disease states.$346,368
P01 · FY2015 · DK · contact PI